- Previous Close
0.0700 - Open
0.0700 - Bid 0.0014 x --
- Ask 1.0000 x --
- Day's Range
0.0700 - 0.0700 - 52 Week Range
0.0012 - 0.6300 - Volume
1,000 - Avg. Volume
40 - Market Cap (intraday)
1.034M - Beta (5Y Monthly) 2.38
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
www.biocuretech.comRecent News: BICTF
View MorePerformance Overview: BICTF
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BICTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BICTF
View MoreValuation Measures
Market Cap
14.62k
Enterprise Value
29.49k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.01
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.83%
Return on Equity (ttm)
-194.71%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.02M
Diluted EPS (ttm)
-0.2600
Balance Sheet and Cash Flow
Total Cash (mrq)
26.78k
Total Debt/Equity (mrq)
3.07%
Levered Free Cash Flow (ttm)
-307.49k